** Protara Therapeutics TARA.O shares down 9.5% to $6.04 in extended trading on planned equity raise. Shares on Mon closed up 12.9% at $6.67
** Cancer and rare-disease treatment firm announces offering of stock and pre-funded warrants; deal size not disclosed
** It intends to use net offering proceeds to fund clinical development of TARA-002, and development of other clinical programs
** TARA shares on Thurs finished session up 70% at $6.02 after co said TARA-002 helped remove all signs of cancer in 72% of patients at six months of treatment for non-muscle invasive bladder cancer (NMIBC) in mid-stage study
** Co has ~20.6 mln shares outstanding for ~$137 mln market cap
** TD Cowen, Cantor, LifeSci Capital, Oppenheimer and Scotiabank jt bookrunners for offering
** TARA shares ended 2023 at $1.88
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。